
Communication from the GPhC regarding Regulatory Concerns
Communication from the GPhC regarding Regulatory Concerns Regarding the Supply and Promotion of Weight-Management Medicines – Mounjaro®, Wegovy® and Related GLP-1 Therapies
Communication from the GPhC regarding Regulatory Concerns Regarding the Supply and Promotion of Weight-Management Medicines – Mounjaro®, Wegovy® and Related GLP-1 Therapies
As part of maintaining professional vigilance and regulatory compliance across pharmacy services, PCL would like to draw attention to several critical issues recently highlighted by the General Pharmaceutical Council (GPhC).
In this blog I want to highlight some critical updates from the General Pharmaceutical Council (GPhC) that every pharmacy professional—whether you’re a pharmacist, technician, or pharmacy owner—should be aware of. These issues have prompted serious regulatory concerns and demand thoughtful consideration and action where appropriate.
Now we have started 2025, this blog highlights the common trends identified from GPhC inspections carried out in 2024.
The GPhC has issued new guidance for distance selling and online pharmacies which came into effect in February 2025.
When operating a pharmacy, the General Pharmaceutical Council (GPhC) will come and inspect you against the pharmacy standards, do you know what evidence you will need to present to demonstrate how your pharmacy adheres to the standards?